


[DPen2, Pen5] Enkephalin

Cat. No.:	HY-P3546
CAS No.:	88373-72-2
Molecular Formula:	C ₃₀ H ₃₉ N ₅ O ₇ S ₂
Molecular Weight:	645.79
Sequence Shortening:	Y-{d-Pen}-GF-[Pen] (Disulfide bridge: d-Pen2-Pen5)
Target:	Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	[DPen2, Pen5] Enkephalin is a δ -opioid receptor selective analog of [Leu5]-Enkephalin (HY-P0288) ^[1] .																
IC₅₀ & Target	δ Opioid Receptor/DOR																
In Vivo	<p>[DPen2, Pen5] Enkephalin (0-3.32 μg/kg, IP) impairs acquisition of an automated jump-up avoidance response in rats and acquisition of a one-way active avoidance response in mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague-Dawley rats (260-280 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0, 1.16, 11.6 μg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP, administered on day 2 prior to presentation of eight training trials, on subsequent one-way avoidance responding.</td> </tr> <tr> <td>Result:</td> <td>Produced a significant impairment of avoidance performance at 1.16 μg/kg, while the 11.6 μg/kg dose was without significant effect.</td> </tr> <tr> <td>Animal Model:</td> <td>Male Sprague-Dawley rats (260-280 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0, 0.332, 3.32 μg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP, administered on day 1 immediately after presentation of two escape-only trials, on subsequent day 2 one-way avoidance responding in the second experiment</td> </tr> <tr> <td>Result:</td> <td>Produced a significant enhancement of avoidance performance at 0.332 μg/kg, while the 3.32 μg/kg dose was without significant effect.</td> </tr> </table>	Animal Model:	Male Sprague-Dawley rats (260-280 g) ^[1]	Dosage:	0, 1.16, 11.6 μ g/kg	Administration:	IP, administered on day 2 prior to presentation of eight training trials, on subsequent one-way avoidance responding.	Result:	Produced a significant impairment of avoidance performance at 1.16 μ g/kg, while the 11.6 μ g/kg dose was without significant effect.	Animal Model:	Male Sprague-Dawley rats (260-280 g) ^[1]	Dosage:	0, 0.332, 3.32 μ g/kg	Administration:	IP, administered on day 1 immediately after presentation of two escape-only trials, on subsequent day 2 one-way avoidance responding in the second experiment	Result:	Produced a significant enhancement of avoidance performance at 0.332 μ g/kg, while the 3.32 μ g/kg dose was without significant effect.
Animal Model:	Male Sprague-Dawley rats (260-280 g) ^[1]																
Dosage:	0, 1.16, 11.6 μ g/kg																
Administration:	IP, administered on day 2 prior to presentation of eight training trials, on subsequent one-way avoidance responding.																
Result:	Produced a significant impairment of avoidance performance at 1.16 μ g/kg, while the 11.6 μ g/kg dose was without significant effect.																
Animal Model:	Male Sprague-Dawley rats (260-280 g) ^[1]																
Dosage:	0, 0.332, 3.32 μ g/kg																
Administration:	IP, administered on day 1 immediately after presentation of two escape-only trials, on subsequent day 2 one-way avoidance responding in the second experiment																
Result:	Produced a significant enhancement of avoidance performance at 0.332 μ g/kg, while the 3.32 μ g/kg dose was without significant effect.																

REFERENCES

[1]. Martinez JL Jr, et al. D-Pen2-[D-Pen5]enkephalin impairs acquisition and enhances retention of a one-way active avoidance response in rats. Peptides. 1992 Sep-Oct;13(5):885-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA